Myogenesis in dysferlin-deficient myoblasts is inhibited by an intrinsic inflammatory response

Neuromuscular Disorders

Volumn 22, Issue 7, 2012, Pages 648-658

  Cohen, Tatiana V ^a   Cohen, Jonathan E ^a   Partridge, Terence A ^a  

^a CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

Author keywords

Immortomouse; Inflammation; Muscle culture; Muscular dystrophy; MyoD; P65 RelA; Thunder of God Vine

Indexed keywords

CELASTROL; DYSFERLIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL NUCLEUS; DISEASE ACTIVITY; DYSFERLINOPATHY; GENE EXPRESSION; IN VITRO STUDY; INFLAMMATION; MOUSE; MUSCLE DEVELOPMENT; MYOBLAST; MYOTUBE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; SYMPTOMATOLOGY; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; UPREGULATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CALRETICULIN; CELLS, CULTURED; GENE EXPRESSION REGULATION; HISTOCOMPATIBILITY ANTIGENS CLASS I; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MUSCLE DEVELOPMENT; MUSCLE PROTEINS; MUSCLE, SKELETAL; MUTATION; NF-KAPPA B; SATELLITE CELLS, SKELETAL MUSCLE; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSCRIPTION FACTOR RELA; TRITERPENES;

EID: 84862212313     PISSN: 09608966     EISSN: 18732364     Source Type: Journal    
DOI: 10.1016/j.nmd.2012.03.002     Document Type: Article

References (49)

1. Liu J., Aoki M., Illa I., et al. Dysferlin, a novel skeletal muscle gene, is mutated in Miyoshi myopathy and limb girdle muscular dystrophy. Nat Genet 1998, 20:31-36.
2. Mahjneh I., Marconi G., Bushby K., Anderson L.V., Tolvanen-Mahjneh H., Somer H. Dysferlinopathy (LGMD2B): a 23-year follow-up study of 10 patients homozygous for the same frameshifting dysferlin mutations. Neuromuscul Disord 2001, 11:20-26.
3. Bashir R., Strachan T., Keers S., et al. A gene for autosomal recessive limb-girdle muscular dystrophy maps to chromosome 2p. Hum Mol Genet 1994, 3:455-457.
4. Bushby K.M. Making sense of the limb-girdle muscular dystrophies. Brain 1999, 122(Pt. 8):1403-1420.
5. Linssen W.H., Notermans N.C., Van der Graaf Y., et al. Miyoshi-type distal muscular dystrophy. Clinical spectrum in 24 Dutch patients. Brain 1997, 120(Pt. 11):1989-1996.
6. Illa I., Serrano-Munuera C., Gallardo E., et al. Distal anterior compartment myopathy: a dysferlin mutation causing a new muscular dystrophy phenotype. Ann Neurol 2001, 49:130-134.
7. Cenacchi G., Fanin M., De Giorgi L.B., Angelini C. Ultrastructural changes in dysferlinopathy support defective membrane repair mechanism. J Clin Pathol 2005, 58:190-195.
8. Fanin M., Angelini C. Muscle pathology in dysferlin deficiency. Neuropathol Appl Neurobiol 2002, 28:461-470.
9. Anderson L.V., Davison K., Moss J.A., et al. Dysferlin is a plasma membrane protein and is expressed early in human development. Hum Mol Genet 1999, 8:855-861.
10. Laval S.H., Bushby K.M. Limb-girdle muscular dystrophies - from genetics to molecular pathology. Neuropathol Appl Neurobiol 2004, 30:91-105.
11. Davis D.B., Delmonte A.J., Ly C.T., McNally E.M. Myoferlin, a candidate gene and potential modifier of muscular dystrophy. Hum Mol Genet 2000, 9:217-226.
12. Bansal D., Campbell K.P. Dysferlin and the plasma membrane repair in muscular dystrophy. Trends Cell Biol 2004, 14:206-213.
13. Bansal D., Miyake K., Vogel S.S., et al. Defective membrane repair in dysferlin-deficient muscular dystrophy. Nature 2003, 423:168-172.
14. Roche J.A., Lovering R.M., Bloch R.J. Impaired recovery of dysferlin-null skeletal muscle after contraction-induced injury in vivo. Neuroreport 2008, 19:1579-1584.
15. de Luna N., Gallardo E., Soriano M., et al. Absence of dysferlin alters myogenin expression and delays human muscle differentiation "in vitro" J Biol Chem 2006, 281:17092-17098.
16. Belanto J.J., Diaz-Perez S.V., Magyar C.E., et al. Dexamethasone induces dysferlin in myoblasts and enhances their myogenic differentiation. Neuromuscul Disord 2010, 20:111-121.
17. Klinge L., Laval S., Keers S., et al. From T-tubule to sarcolemma: damage-induced dysferlin translocation in early myogenesis. FASEB J 2007, 21:1768-1776.
18. Rawat R., Cohen T.V., Ampong B., et al. Inflammasome up-regulation and activation in dysferlin-deficient skeletal muscle. Am J Pathol 2010, 176:2891-2900.
19. Luo G., Hershko D.D., Robb B.W., Wray C.J., Hasselgren P.O. IL-1beta stimulates IL-6 production in cultured skeletal muscle cells through activation of MAP kinase signaling pathway and NF-kappa B. Am J Physiol Regul Integr Comp Physiol 2003, 284:R1249-R1254.
20. Sarkar A., Duncan M., Hart J., Hertlein E., Guttridge D.C., Wewers M.D. ASC directs NF-kappaB activation by regulating receptor interacting protein-2 (RIP2) caspase-1 interactions. J Immunol 2006, 176:4979-4986.
21. Wang H., Hertlein E., Bakkar N., et al. NF-kappaB regulation of YY1 inhibits skeletal myogenesis through transcriptional silencing of myofibrillar genes. Mol Cell Biol 2007, 27:4374-4387.
22. Peterson J.M., Bakkar N., Guttridge D.C. NF-kappaB signaling in skeletal muscle health and disease. Curr Top Dev Biol 2011, 96:85-119.
23. Guttridge D.C., Mayo M.W., Madrid L.V., Wang C.Y., Baldwin A.S. NF-kappaB-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia. Science 2000, 289:2363-2366.
24. Acharyya S., Villalta S.A., Bakkar N., et al. Interplay of IKK/NF-kappaB signaling in macrophages and myofibers promotes muscle degeneration in Duchenne muscular dystrophy. J Clin Invest 2007, 117:889-901.
25. Peterson J.M., Guttridge D.C. Skeletal muscle diseases, inflammation, and NF-kappaB signaling: insights and opportunities for therapeutic intervention. Int Rev Immunol 2008, 27:375-387.
26. Morgan J.E., Beauchamp J.R., Pagel C.N., et al. Myogenic cell lines derived from transgenic mice carrying a thermolabile T antigen: a model system for the derivation of tissue-specific and mutation-specific cell lines. Dev Biol 1994, 162:486-498.
27. Ho M., Post C.M., Donahue L.R., et al. Disruption of muscle membrane and phenotype divergence in two novel mouse models of dysferlin deficiency. Hum Mol Genet 2004, 13:1999-2010.
28. Pfaffl M.W. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001, 29:e45.
29. Demonbreun A.R., Fahrenbach J.P., Deveaux K., Earley J.U., Pytel P., McNally E.M. Impaired muscle growth and response to insulin-like growth factor 1 in dysferlin-mediated muscular dystrophy. Hum Mol Genet 2011, 20:779-789.
30. Chiu Y.H., Hornsey M.A., Klinge L., et al. Attenuated muscle regeneration is a key factor in dysferlin-deficient muscular dystrophy. Hum Mol Genet 2009, 18:1976-1989.
31. Millay D.P., Maillet M., Roche J.A., et al. Genetic manipulation of dysferlin expression in skeletal muscle: novel insights into muscular dystrophy. Am J Pathol 2009, 175:1817-1823.
32. Weller A.H., Magliato S.A., Bell K.P., Rosenberg N.L. Spontaneous myopathy in the SJL/J mouse: pathology and strength loss. Muscle Nerve 1997, 20:72-82.
33. Bittner R.E., Anderson L.V., Burkhardt E., et al. Dysferlin deletion in SJL mice (SJL-Dysf) defines a natural model for limb girdle muscular dystrophy 2B. Nat Genet 1999, 23:141-142.
34. Baudy A.R., Saxena N., Gordish H., Hoffman E.P., Nagaraju K. A robust in vitro screening assay to identify NF-kappaB inhibitors for inflammatory muscle diseases. Int Immunopharmacol 2009, 9:1209-1214.
35. Lu A., Proto J.D., Guo L., et al. NF-kappaB negatively impacts the myogenic potential of muscle-derived stem cells. Mol Ther 2012, 20:661-668.
36. De Luna N., Gallardo E., Sonnet C., et al. Role of thrombospondin 1 in macrophage inflammation in dysferlin myopathy. J Neuropathol Exp Neurol 2010, 69:643-653.
37. 2+-triggered exocytosis. Curr Opin Cell Biol 2010, 22:496-505.
38. Idone V., Tam C., Andrews N.W. Two-way traffic on the road to plasma membrane repair. Trends Cell Biol 2008, 18:552-559.
39. Han R. Muscle membrane repair and inflammatory attack in dysferlinopathy. Skelet Muscle 2011, 1:10.
40. Johnson C.P., Chapman E.R. Otoferlin is a calcium sensor that directly regulates SNARE-mediated membrane fusion. J Cell Biol 2010, 191:187-197.
41. Reddy A., Caler E.V., Andrews N.W. Plasma membrane repair is mediated by Ca(2+)-regulated exocytosis of lysosomes. Cell 2001, 106:157-169.
42. Doherty K.R., Cave A., Davis D.B., et al. Normal myoblast fusion requires myoferlin. Development 2005, 132:5565-5575.
43. Mitchell C.A., Grounds M.D., Papadimitriou J.M. The genotype of bone marrow-derived inflammatory cells does not account for differences in skeletal muscle regeneration between SJL/J and BALB/c mice. Cell Tissue Res 1995, 280:407-413.
44. Maley M.A., Fan Y., Beilharz M.W., Grounds M.D. Intrinsic differences in MyoD and myogenin expression between primary cultures of SJL/J and BALB/C skeletal muscle. Exp Cell Res 1994, 211:99-107.
45. Roche J.A., Lovering R.M., Roche R., Ru L.W., Reed P.W., Bloch R.J. Extensive mononuclear infiltration and myogenesis characterize recovery of dysferlin-null skeletal muscle from contraction-induced injuries. Am J Physiol Cell Physiol 2010, 298:C298-C312.
46. Potgieter M., Pretorius E., Van der Merwe C.F., et al. Histological assessment of SJL/J mice treated with the antioxidants coenzyme Q10 and resveratrol. Micron 2011, 42:275-282.
47. Han R., Frett E.M., Levy J.R., et al. Genetic ablation of complement C3 attenuates muscle pathology in dysferlin-deficient mice. J Clin Invest 2010, 120:4366-4374.
48. Kannaiyan R., Shanmugam M.K., Sethi G. Molecular targets of celastrol derived from Thunder of God Vine: potential role in the treatment of inflammatory disorders and cancer. Cancer Lett 2011, 303:9-20.
49. Sethi G., Ahn K.S., Pandey M.K., Aggarwal B.B. Celastrol, a novel triterpene, potentiates TNF-induced apoptosis and suppresses invasion of tumor cells by inhibiting NF-kappaB-regulated gene products and TAK1-mediated NF-kappaB activation. Blood 2007, 109:2727-2735.